Ted Rosen, MD

Articles by Ted Rosen, MD

14-Month-Old With Multiple Dome-Shaped Yellow Papulonodules

ByTed Rosen, MD

June 10th 2011

A 71-Year-Old Male Presents for Evaluation of Painless Bump on His Chin

ByTed Rosen, MD

May 26th 2011

Persistent, Intensely Painful Ulceration of the Contralateral Breast

ByTed Rosen, MD

May 16th 2011

A 71-year-old woman was receiving a multi-agent chemotherapeutic regimen following a lumpectomy for breast cancer. After the second round of treatment, she presented for medical care due to persistent, intensely painful ulceration of the contralateral breast.

Photosensitive Facial Rash Depicted Along with Polyarticular Arthralgias

ByTed Rosen, MD

April 29th 2011

Painful, Hot Fluctuant Lump on Chin of Breast Cancer Patient

ByTed Rosen, MD

April 15th 2011

Rapidly Growing Pedal Lesions Following Chemotherapy

ByTed Rosen, MD

April 1st 2011

Progressively Enlarging Mass on the Lower Back

ByTed Rosen, MD

March 21st 2011

A 29-year-old man, previously in excellent health, presented with a progressively enlarging mass on the lower back of one-year’s duration. What would be the best initial course of action at this point?

Pruritic Discoloration Following ABVD Therapy

ByTed Rosen, MD

March 7th 2011

Ted Rosen, MD

Articles by Ted Rosen, MD

14-Month-Old With Multiple Dome-Shaped Yellow Papulonodules

A 71-Year-Old Male Presents for Evaluation of Painless Bump on His Chin

Persistent, Intensely Painful Ulceration of the Contralateral Breast

Photosensitive Facial Rash Depicted Along with Polyarticular Arthralgias

Painful, Hot Fluctuant Lump on Chin of Breast Cancer Patient

Rapidly Growing Pedal Lesions Following Chemotherapy

Progressively Enlarging Mass on the Lower Back

Pruritic Discoloration Following ABVD Therapy

Trending on CancerNetwork

Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer

BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma

Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care

Proton Therapy Does Not Improve Survival in Hepatocellular Carcinoma

Lirafugratinib Approval Adds a Third FGFR2 Inhibitor in Cholangiocarcinoma